Brief: MEI Pharma Highlights Recommendation By Leading Independent Proxy Advisory Firm ISS To Vote 'FOR' Pending Transaction With Infinity Pharmaceuticals
05/07/2023 13:17
July 5 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA HIGHLIGHTS RECOMMENDATION BY LEADING
INDEPENDENT
PROXY ADVISORY FIRM ISS TO VOTE “FOR” PENDING TRANSACTION WITH
INFINITY PHARMACEUTICALS
Source text for Eikon: ID:nBw8SsHxfa
Further company coverage: MEIP.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations